Depression News

Pharmaceutical company Sage Therapeutics and biotech firm Biogen announced completion of a rolling submission of a new drug application to the FDA for zuranolone for the treatment of major depressive disorder and postpartum depression.

Two pharmaceutical firms announced they have started a phase 2/3 trial to evaluate the efficacy of ulotaront, a trace amine-associated receptor 1 agonist, as an adjunctive therapy for major depressive disorder treatment, according to a joint press release.

Pregnant women who participated in weekly wellness classes were half as likely to be depressed up to 8 years later, compared with women who received standard care, researchers reported in the Journal of Consulting and Clinical Psychology.

The FDA has issued a “study may proceed” letter to biopharmaceutical company Vistagen for its newly filed investigational new drug application for the clinical development of PH10, a treatment for major depressive disorder.

EmbarkNeuro, a neuroscience biotech company formerly known as Ancora Bio, announced its phase 2 trial is under way for ANC-501, a first-in-class vasopressin 1b receptor antagonist for the treatment of major depressive disorder.

According to a recently released survey, 45% of Americans are worried about their mental health this holiday season.

Janssen has announced positive results from the phase 3 ESCAPE-TRD trial, which evaluated flexibly dosed intranasal esketamine for treatment-resistant major depressive disorder.

The biggest news on Healio Psychiatry over the last month was the controversy over daylight saving time.

Teachers showed a significantly higher prevalence of negative mental health outcomes compared with health care and office workers during the COVID-19 pandemic, researchers reported in Educational Researcher.

Biomind Labs Inc. announced that the FDA has given the company Investigational New Drug clearance related to its new chemical entity, Triptax, for the treatment of treatment-resistant depression.